IDH3A and glioblastoma: Notably, one patient with isocitrate dehydrogenase (IDH)-mutant GBM experienced a greater than 16-month survival, and CD4+ T cell count positively correlated with survival; however, according to the 2021 WHO classification of central nervous system tumors, the presence of an IDH mutation is not in line with the current definition of GBM.